GI Unit, Molecular Medicine Centre, University of Edinburgh, UK 002 ANALYSIS OF CCL20 VARIANTS IN IBD PROVIDES FURTHER EVIDENCE FOR GENETIC HETEROGENEITY IN DISEASE SUSCEPTIBILITYĬ. We confirm the association with HLA-DRB1*0103 and further demonstrate that this allele may predict disease course. We confirmed the association with DRB1*0103 (14.7% cases v 2.7% controls p = 5.5×10 −9 RR = 3.2) and report the novel association of this allele with time to first surgical event (Log Rank p = 0.002) and time to first “severity event” (resection/diversion ileostomy/Infliximab) (p = 0.001).Ĭonclusions: This study reports the clinical manifestations of isolated colonic CD. 12% of the entire cohort received ⩾1 Infliximab infusion and 19% underwent colonic resection for severe disease (cumulative risk at 2 years, 10.6% 5 years, 17.1% 10 years, 32.8%). Stricturing colonic disease was noted in 10% of patients. 29.4% and 14.0% reported a family history (1st or 2nd degree) of CD and UC respectively. The mean age at diagnosis was 30.7 years. Results: 136 (10.3%) patients were classified with L2 disease after a median follow up of 10.8 years (range 1.4–39.8). HLA genotyping was performed using PCR-SSP. Only patients with a normal small bowel enema (70%), ileoscopy alone (30%), or both (20%) were included. Methods: Patients with L2 disease were identified from a database of 1318 CD patients. (2) To confirm the association with HLA-DRB1*0103, reported in smaller cohorts, and to investigate its role in predicting disease course and need for surgery. Aims: (1) To describe the clinical features and natural history of isolated colonic CD in a rigorously characterised patient cohort.
0 kommentar(er)
